Short Bowel Syndrome (SBS)
9
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
Role of the Microbiota in Intestinal Adaptation During Short Bowel Syndrome
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
TED_ORG: Study on Short Bowel Syndrome
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies